Most of us had read the “Pestell” article with

Most of us had read the “Pestell” article with Drs. Cristofanilli, Ruin, Jiao and Wang from beginning of last year (actually I increased my position when this was first reported).

This, and the recently peer-reviewed paper is (are) a VERY powerful paper for hose interested in Oncology applications of VX (Leronlimab).

Why? It poses several moas in regards to breast cancer:

Quote:

---

1) Leronlimab blocks human CCL3- and CCL4-induced Ca+ 2 responses in human breast cancer cells
2) Leronlimab blocks CCR5-mediated invasion of human breast cancer cells into the extracellular matrix
) Leronlimab prevents breast cancer cell metastasis in a mouse lung metastasis model
4) Leronlimab reduces the volume of established progressing human breast cancer metastasis in mice
) Leronlimab enhances cell killing by DNA damage-inducing chemotherapy agents used for breast cancer treatment

---

I don’t know about you but this is extraordinary: If a company has a drug that can reduce/stop metastasis by itself this is a humongous achievement. The therapeutic application is straightforward and the primary end-point is a very low hanging fruit (some months of extended OS).

Now, if we throw-in the capability to reduce tumors and enhancing cell killing by chemo-induced damaged cells, basically we have an army attacking the cancer from all fronts.

Of course, some of this has to be transferred from murine to human. What I am trying to say is: if this works this is just ginormous !!!

Isn’t it ??? (or I am being naïve ??)

Now talking money, below a list of best sellers …

https://truecostofhealthcare.org/pharmas-50-best-sellers/


Needless to say: we going into this list will mean, yes, we have heard this before: “three digit SP”.

Again, am I being naïve ???. As far as I am concerned, if this works out we will be somewhere at the beginning of this list when everything pans out.

Where in the "three digit " I leave it to you .